Journal
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
Volume 33, Issue 1, Pages 61-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.idc.2018.10.003
Keywords
Human African trypanosomiasis; Trypanosoma brucei gambiense; Trypanosoma brucei rhodesiense; Clinical presentation; Diagnosis; Treatment
Categories
Ask authors/readers for more resources
Control efforts have considerably reduced the prevalence of human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in West/Central Africa and to Trypanosoma brucei rhodesiense in East Africa. Management of T brucei gambiense HAT has recently improved, with new antibody-based rapid diagnostic tests suited for mass screening and clinical care, and simpler treatments, including the nifurtimox-eflornithine combination therapy and the new oral drug fexinidazole to treat the second stage of the disease. In contrast, no major advance has been achieved for the treatment of T brucei rhodesiense HAT, a zoonosis that occasionally affects short-term travelers to endemic areas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available